Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Opiant Pharmaceuticals, Inc. - Common Stock (NQ:OPNT)

N/A UNCHANGED
Last Price Updated: 4:00 PM EST, Mar 1, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Opiant Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 Next >
News headline image
110 Biggest Movers From Friday ↗
Gainers ShiftPixy, Inc. (NASDAQ: PIXY) shares jumped 154.9% to close at $0.51. ShiftPixy reported board approval special dividend to shareholders in form of common shares of Industrial Human Capital. 
Via Benzinga
News headline image
Why Opiant Pharmaceuticals Shares Are Soaring Today ↗
 
Via Benzinga
News headline image
Earnings Scheduled For November 11, 2021 ↗
Companies Reporting Before The Bell • NICE (NASDAQ:NICE) is likely to report quarterly earnings at $1.58 per share on revenue of $465.75 million. • Reshape... 
Via Benzinga
News headline image
Earnings Scheduled For August 11, 2022 ↗
Companies Reporting Before The Bell • Magic Software (NASDAQ:MGIC) is projected to report quarterly earnings at $0.27 per share on revenue of $131.70 million. 
Via Benzinga
News headline image
Biotech Daily: Regulatory Setback For CorMedix, Mersana & GSK In Cancer Pact, BARDA Funding For Opioid Overdose Hopeful ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
News headline image
Opiant Pharma Secures Additional BARDA Funding For Opioid Overdose Treatment ↗
 
Via Benzinga
Small-Cap Psychedelic Play Vying for Future Leadership in Addiction Treatment (AXSM, AWKNF, BICX, OPNT, ALKS, PFE, AMPH, OMER)
Via AB Newswire
News headline image
Stocks That Hit 52-Week Lows On Friday ↗
On Friday, 153 companies set new 52-week lows. 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Wednesday's Intraday Session ↗
 
Via Benzinga
News headline image
The Daily Biotech Pulse: Pfizer Acquires Migraine Drugmaker For $11B, Biogen Files For Second Alzheimer's Drug Approval, Longeveron CEO Leaves ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
News headline image
99 Biggest Movers From Yesterday ↗
Gainers Armstrong Flooring, Inc. (NYSE: AFI) shares jumped 237% to settle at $0.49 on Wednesday after a 13D filing showed Esopus Creek Advisors LLC disclosed a 5.1% active stake in the company. 
Via Benzinga
News headline image
Earnings Scheduled For May 10, 2022 ↗
Companies Reporting Before The Bell • The Middleby (NASDAQ:MIDD) is expected to report quarterly earnings at $2.10 per share on revenue of $935.99 million. 
Via Benzinga
News headline image
A Preview Of Opiant Pharmaceuticals's Earnings ↗
Opiant Pharmaceuticals (NASDAQ:OPNT) is set to give its latest quarterly earnings report on Tuesday, 2022-05-10. Here's what investors need to know before the announcement. Analysts estimate that... 
Via Benzinga
News headline image
70 Biggest Movers From Friday ↗
Gainers GTY Technology Holdings Inc. (NASDAQ: GTYH) shares climbed 115.2% to close at $6.09 as the company agreed to be acquired by GI Partners. Vaxxinity, Inc. (NASDAQ: VAXX)... 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Friday's Intraday Session ↗
 
Via Benzinga
News headline image
48 Stocks Moving In Friday's Mid-Day Session ↗
Gainers Belite Bio Inc. ADR (NASDAQ: BLTE) shares surged 144.8% to $14.69. Belite Bio priced its 6 million ADS IPO at $6 per ADS. GTY Technology Holdings Inc. (NASDAQ:... 
Via Benzinga
News headline image
The Daily Biotech Pulse: Moderna Seeks FDA Approval For COVID-19 Shot For Children 2-6, Tax Disclosure For Amgen, Fast Track Tags For SQZ Biotech, Timber Pharma Candidates ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
News headline image
President Biden To Outline Strategy To Tackle Drug Addiction, Overdose: Reuters ↗
 
Via Benzinga
News headline image
Looking Into Opiant Pharmaceuticals's Return On Capital Employed ↗
According to Benzinga Pro, during Q4, Opiant Pharmaceuticals (NASDAQ:OPNT) earned $752.33 thousand, a 77.98% increase from the preceding quarter. Opiant Pharmaceuticals's sales... 
Via Benzinga
News headline image
Opiant Pharmaceuticals: Q4 Earnings Insights ↗
Opiant Pharmaceuticals (NASDAQ:OPNT) reported its Q4 earnings results on Tuesday, March 15, 2022 at 04:00 PM. Here's what investors need to know about the announcement.... 
Via Benzinga
News headline image
Opiant Pharmaceuticals's Earnings Outlook ↗
Opiant Pharmaceuticals (NASDAQ:OPNT) is set to give its latest quarterly earnings report on Tuesday, 2022-03-15. Here's what investors need to know before the announcement.... 
Via Benzinga
News headline image
Opiant's Multi-Dose Nasal Nalmefene Shows Safety, Tolerability In Opioid Overdose ↗
Opiant Pharmaceuticals Inc (NASDAQ: OPNT)  
Via Benzinga
News headline image
The Daily Biotech Pulse: Pfizer-BioNTech Starts Omicron-Specific Vaccine Study, J&J Misses On Topline, Sierra Oncology Reports Positive Data ↗
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Pfizer, BioNTech Initiates Study Of Omicron-Based Vaccine Candidate Pfizer,... 
Via Benzinga
News headline image
Earnings Scheduled For March 15, 2022 ↗
Companies Reporting Before The Bell • IDEAYA Biosciences (NASDAQ:IDYA) is likely to report quarterly loss at $0.31 per share on revenue of $8.98 million. • Citi... 
Via Benzinga
News headline image
Under BARDA Contract, Opiant Pharma Secures Additional Funding Of $2M For Opioid Overdose Program ↗
The Biomedical Advanced Research and Development Authority (BARDA) will provide additional funding of up to $2.2 million to support Opiant Pharmaceuticals Inc's... 
Via Benzinga
News headline image
The Daily Biotech Pulse: Kura Lifts Clinical Hold On Blood Cancer Trial, Intuitive Surgical Earnings, Sorrento's Omicron Antibody Treatment Effective ↗
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Kura Announces Lifting Of Clinical Hold On Phase 1 Blood Cancer Study Kura... 
Via Benzinga
News headline image
Opiant Pharma Starts Dosing In OPNT002 Mid-Stage Study For Alcohol Use Disorder ↗
Opiant Pharmaceuticals Inc (NASDAQ: OPNT) has dosed the first patient in Phase 2 trial of OPNT002, nasal naltrexone, for Alcohol Use Disorder (AUD). The... 
Via Benzinga
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For December 9, 2021 ↗
Upgrades According to BMO Capital, the prior rating for Nuvei Corp (NASDAQ: 
Via Benzinga
News headline image
The Daily Biotech Pulse: NRx's Zyesami Face Regulatory Rejection, Puma Slumps On Q3 Miss, Pfizer Has Good Tidings On Oral Antiviral COVID-19 Pill ↗
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus NRx's COVID-19 Drug Fails to Get Authorization From FDA Due To... 
Via Benzinga
News headline image
The Daily Biotech Pulse: Moderna Invests In Africa, Amgen Announces Neuroscience R&D Collaboration, Decision Day For Chemocentryx, Biophytis To Restate Results ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 6) Enanta Pharmaceuticals, Inc... 
Via Benzinga
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.